TABLE OF CONTENTS
1 INTRODUCTION 23
1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 PRODUCT TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PORTERS FIVE FORCES MODEL 45
4.2 PESTEL ANALYSIS 46
5 INDUSTRY INSIGHTS: EUROPE NASAL SPRAY MARKET 47
5.1 INDUSTRY INSIGHTS 47
6 REGULATIONS: EUROPE NASAL SPRAY MARKET 48
6.1 REGULATORY SCENARIO IN EUROPE 48
7 MARKET OVERVIEW 49
7.1 DRIVERS 51
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES 51
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA 51
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY 52
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY 53
7.2 RESTRAINTS 54
7.2.1 PRODUCT RECALLS 54
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS 55
7.3 OPPORTUNITIES 56
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY 56
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS 56
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS 57
7.4 CHALLENGES 57
7.4.1 REGULATORY HURDLES 57
7.4.2 ADDICTION TO NASAL SPRAY 58
8 EUROPE NASAL SPRAY MARKET, BY PRODUCT TYPE 59
8.1 OVERVIEW 60
8.2 DECONGESTION NASAL SPRAY 63
8.3 STEROID NASAL SPRAY 64
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY 65
8.5 OTHERS 66
9 EUROPE NASAL SPRAY MARKET, BY CONTAINER DESIGN 67
9.1 OVERVIEW 68
9.2 PUMP BOTTLES 71
9.3 PRESSURIZED CANISTERS 72
10 EUROPE NASAL SPRAY MARKET, BY DOSAGE FORM 73
10.1 OVERVIEW 74
10.2 MULTI DOSE 77
10.3 UNIT/SINGLE DOSE 78
10.4 BI DOSE 79
11 EUROPE NASAL SPRAY MARKET, BY THERAPEUTIC CLASS 81
11.1 OVERVIEW 82
11.2 ANTIHISTAMINE 85
11.3 NASAL STEROIDS 86
11.4 MAST CELL INHIBITOR 87
11.5 ANTICHOLINERGIC 88
12 EUROPE NASAL SPRAY MARKET, BY APPLICATION 89
12.1 OVERVIEW 90
12.2 NASAL CONGESTION 93
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS 94
12.4 CENTRAL NERVOUS SYSTEM DISORDERS 95
12.5 VACCINATION 96
12.6 OTHERS 97
13 EUROPE NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY 98
13.1 OVERVIEW 99
13.2 PRESCRIBED 102
13.3 OVER THE COUNTER 103
14 EUROPE NASAL SPRAY MARKET, BY END USER 105
14.1 OVERVIEW 106
14.2 HOME CARE SETTINGS 109
14.3 HOSPITALS 110
14.4 CLINICS 111
14.5 COMMUNITY HEALTH CARE 112
15 EUROPE NASAL SPRAY MARKET, BY REGION 113
15.1 EUROPE 114
15.1.1 GERMANY 122
15.1.2 U.K. 124
15.1.3 FRANCE 126
15.1.4 ITALY 128
15.1.5 SPAIN 130
15.1.6 SWITZERLAND 132
15.1.7 NETHERLANDS 134
15.1.8 BELGIUM 136
15.1.9 RUSSIA 138
15.1.10 TURKEY 140
15.1.11 REST OF EUROPE 142
16 EUROPE NASAL SPRAY MARKET, COMPANY LANDSCAPE 143
16.1 COMPANY SHARE ANALYSIS: EUROPE 143
17 SWOT ANALYSIS 144
18 COMPANY PROFILE 145
18.1 GLAXOSMITHKLINE PLC. 145
18.1.1 COMPANY SNAPSHOT 145
18.1.2 REVENUE ANALYSIS 145
18.1.3 COMPANY SHARE ANALYSIS 146
18.1.4 PRODUCT PORTFOLIO 146
18.1.5 RECENT DEVELOPMENTS 146
18.2 PFIZER INC. 148
18.2.1 COMPANY SNAPSHOT 148
18.2.2 REVENUE ANALYSIS 148
18.2.3 COMPANY SHARE ANALYSIS 149
18.2.4 PRODUCT PORTFOLIO 149
18.2.5 RECENT DEVELOPMENTS 149
18.3 EMERGENT 151
18.3.1 COMPANY SNAPSHOT 151
18.3.2 REVENUE ANALYSIS 151
18.3.3 COMPANY SHARE ANALYSIS 152
18.3.4 PRODUCT PORTFOLIO 152
18.3.5 RECENT DEVELOPMENT 152
18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 153
18.4.1 COMPANY SNAPSHOT 153
18.4.2 REVENUE ANALYSIS 153
18.4.3 COMPANY SHARE ANALYSIS 154
18.4.4 PRODUCT PORTFOLIO 154
18.4.5 RECENT DEVELOPMENT 154
18.5 CATALENT, INC. 155
18.5.1 COMPANY SNAPSHOT 155
18.5.2 REVENUE ANALYSIS 155
18.5.3 COMPANY SHARE ANALYSIS 156
18.5.4 PRODUCT PORTFOLIO 156
18.5.5 RECENT DEVELOPMENTS 156
18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 158
18.6.1 COMPANY SNAPSHOT 158
18.6.2 REVENUE ANALYSIS 158
18.6.3 PRODUCT PORTFOLIO 159
18.6.4 RECENT DEVELOPMENTS 159
18.7 AISHWARYA GROUP 160
18.7.1 COMPANY SNAPSHOT 160
18.7.2 PRODUCT PORTFOLIO 160
18.7.3 RECENT DEVELOPMENTS 160
18.8 ASSERTIO THERAPEUTICS, INC. 161
18.8.1 COMPANY SNAPSHOT 161
18.8.2 REVENUE ANALYSIS 161
18.8.3 PRODUCT PORTFOLIO 162
18.8.4 RECENT DEVELOPMENT 162
18.9 AURENA LABORATORIES. 163
18.9.1 COMPANY SNAPSHOT 163
18.9.2 PRODUCT PORTFOLIO 163
18.9.3 RECENT DEVELOPMENTS 163
18.10 BAYER AG 165
18.10.1 COMPANY SNAPSHOT 165
18.10.2 REVENUE ANALYSIS 165
18.10.3 COMPANY SHARE ANALYSIS 166
18.10.4 PRODUCT PORTFOLIO 166
18.10.5 RECENT DEVELOPMENTS 166
18.11 CIPLA INC. 168
18.11.1 COMPANY SNAPSHOT 168
18.11.2 REVENUE ANALYSIS 168
18.11.3 PRODUCT PORTFOLIO 169
18.11.4 RECENT DEVELOPMENT 169
18.12 J PHARMACEUTICALS. 170
18.12.1 COMPANY SNAPSHOT 170
18.12.2 PRODUCT PORTFOLIO 170
18.12.3 RECENT DEVELOPMENTS 170
18.13 LEEFORD HEALTHCARE LTD 171
18.13.1 COMPANY SNAPSHOT 171
18.13.2 PRODUCT PORTFOLIO 171
18.13.3 RECENT DEVELOPMENTS 171
18.14 ST. RENATUS. 172
18.14.1 COMPANY SNAPSHOT 172
18.14.2 PRODUCT PORTFOLIO 172
18.14.3 RECENT DEVELOPMENTS 172
18.15 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD) 173
18.15.1 COMPANY SNAPSHOT 173
18.15.2 REVENUE ANALYSIS 173
18.15.3 PRODUCT PORTFOLIO 174
18.15.4 RECENT DEVELOPMENTS 174
18.16 ULTRATECH INDIA LIMITED 175
18.16.1 COMPANY SNAPSHOT 175
18.16.2 PRODUCT PORTFOLIO 175
18.16.3 RECENT DEVELOPMENTS 175
18.17 VIATRIS INC. 176
18.17.1 COMPANY SNAPSHOT 176
18.17.2 REVENUE ANALYSIS 176
18.17.3 COMPANY SHARE ANALYSIS 177
18.17.4 PRODUCT PORTFOLIO 177
18.17.5 RECENT DEVELOPMENT 177
19 QUESTIONNAIRE 178
20 RELATED REPORTS 182

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.